Evaluation of [11C]-methionine positron emission computerised tomography (PET CT) in diagnosing neurofibromatosis 1(NF1) - malignant peripheral nerve sheath tumours (MPNST) - Methionine PET

Guys' and St. Thomas' NHS Foundation Trust0 个研究点开始时间: 2010年12月13日最近更新: 2014年5月12日

试验速览

暂无简介。

•Patients over 16 years to 80 years fulfilling diagnostic criteria for NF1 /mosaic NF1 who have symptomatic plexiform or subcutaneous neurofibromas - persistent pain, rapid increase in size, change in texture, new or unexplained neurological deficit.
•Note: in mosaic NF1 clinical signs of NF1 restricted to one area of the body as the genetic change occurs after fertilisation. In generalised NF1 the genetic change occurs before fertilisation.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Any prior treatment for the plexiform neurofibroma with chemotherapy or radiotherapy
•2. History of recent significant cardiac arrhythmia
•3. Concurrent congestive heart failure or prior history of class III / IV cardiac disease
•4. Any other condition which in the Investigator’s opinion would not make the patient a good can candidate for the clinical trial
•5. Patients who are pregnant will be excluded. If there is any doubt about pregnancy a pregnancy test will be taken.
•6. Patients who are breast feeding

发起方

Guys' and St. Thomas' NHS Foundation Trust